Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation Expense (2017 - 2025)

Vanda Pharmaceuticals' Depreciation Expense history spans 9 years, with the latest figure at $304000.0 for Q4 2025.

  • On a quarterly basis, Depreciation Expense rose 37.56% to $304000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 28.41% increase, with the full-year FY2025 number at $1.1 million, up 28.41% from a year prior.
  • Depreciation Expense hit $304000.0 in Q4 2025 for Vanda Pharmaceuticals, up from $301000.0 in the prior quarter.
  • Over the last five years, Depreciation Expense for VNDA hit a ceiling of $345000.0 in Q1 2021 and a floor of $200000.0 in Q3 2023.
  • Historically, Depreciation Expense has averaged $273100.0 across 5 years, with a median of $287500.0 in 2022.
  • Biggest five-year swings in Depreciation Expense: tumbled 33.11% in 2023 and later surged 39.35% in 2025.
  • Tracing VNDA's Depreciation Expense over 5 years: stood at $337000.0 in 2021, then decreased by 15.73% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then rose by 7.8% to $221000.0 in 2024, then surged by 37.56% to $304000.0 in 2025.
  • Business Quant data shows Depreciation Expense for VNDA at $304000.0 in Q4 2025, $301000.0 in Q3 2025, and $267000.0 in Q2 2025.